Q2 2024 Maravai LifeSciences Holdings Inc Earnings Call Transcript
Key Points
- Reported $73 million in revenue for Q2 2024, showing solid financial performance.
- Cash on hand at the end of the quarter was $573 million, indicating strong liquidity.
- Successful launch of new products, including catalog mRNA offerings and IVT enzymes, which exceeded sales expectations.
- Completion of key milestones at the Flanders facilities, enhancing manufacturing capabilities and operational risk mitigation.
- Strong market response to new product introductions, reflecting effective innovation and customer engagement.
- GAAP net loss before non-controlling interests was $14 million for Q2 2024, compared to a net loss of $12 million in Q2 2023.
- Adjusted EBITDA margin was 23%, trailing internal expectations and showing volatility over the past six quarters.
- Higher start-up costs and preparedness expenses tied to the Flanders facility impacted profitability.
- Decline in Biologic Safety Testing segment revenue, particularly due to unexpected drops in China.
- Incremental expenses in R&D efforts and collaborations, such as with Johns Hopkins, added to operational costs.
Please stand by for streaming text. Thank you for standing by, and welcome to the marvelous Life Sciences Second Quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you'd like to ask a question, simply press star, followed by the number one on your telephone keypad. If you will, to withdraw your question again, press the star one. Thank you. I'd now like to turn the call over to Debra Hart, Head of Investor Relations. You may begin.
Good afternoon, everyone. Thanks for joining us on our second quarter 2024 earnings call. Our press release and the slides accompanying today's call are posted on our website and available at investors dot Marvell.com. You can see on our agenda for today on Slide 2 for Kay will provide a business update, and Kevin will review our financial results and guidance through Birch President of nucleic acid production that he buys CEO, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
